CLIN2 Awards: Funding Opportunity for Clinical Trials supports organizations conducting stem cell-based or genetic therapy trials to address serious unmet medical needs and advance toward marketing approval.
CIRM removed the October 23, 2026 mandatory-consultation deadline notice and announced an updated CLIN2 Program Announcement. Submission instructions now specify that only the PI or delegate can start an application, the PI cannot be changed afterward, and most CIRM applications require both PI submission and verified organizational-official approval.
CIRM’s Discovery Stage Research program funds collaborative, innovative basic research to advance breakthroughs in regenerative medicine and stem cell biology, focusing on foundational science and early-stage discoveries.
Clinical Innovator Award supports researchers conducting early-phase immunotherapy trials in chordoma, funding clinical investigation to move promising concepts toward potential patient impact.
Preclinical Development supports researchers developing stem cell-based and genetic therapies, funding candidate optimization, preclinical studies, and trial startup to advance toward first-in-human trials.
Clinical Cancer Research supports investigators conducting patient-centered cancer trials and early-detection studies to improve treatment options, enable earlier intervention, and enhance quality of life.
MSCRF Clinical Program supports organizations conducting human stem cell-based clinical research in Maryland to advance therapies for human diseases, injuries, and conditions and address unmet medical needs.